Hold tofacitinib during hospitalization for fever in rheumatoid arthritis patients.
Tofacitinib should be temporarily discontinued when a patient with rheumatoid arthritis is hospitalized with fever until the source of infection is identified and adequately treated. This recommendation is based on clear guideline consensus that tofacitinib should be avoided during active serious infections 1.
Rationale for Holding Tofacitinib
The decision to hold tofacitinib during acute febrile illness is driven by several key considerations:
Infection Risk Profile
- Tofacitinib carries significant infection-related warnings, including a black box warning for serious infections (tuberculosis, invasive fungal infections, bacterial, viral, and opportunistic pathogens) 2
- Real-world data demonstrates tofacitinib has a 1.41-fold higher risk of hospitalization for serious infection compared to etanercept and approximately 1.20-fold higher risk versus abatacept 3
- The drug shows a 2-fold higher risk of herpes zoster compared to all biologic DMARDs 3
Pharmacokinetic Advantages
The short half-life of tofacitinib actually works in your favor here:
- Immunosuppressive effects reverse rapidly after discontinuation, as evidenced by rapid disease activity increases when therapy is interrupted 4
- This means holding the drug for 3-7 days during acute infection workup poses minimal risk of RA flare while substantially reducing infection-related morbidity
- The drug can be safely restarted once infection is controlled
When to Resume Tofacitinib
Restart tofacitinib only after:
- Fever has resolved for at least 24-48 hours without antipyretics
- Source of infection is identified and appropriate antimicrobial therapy initiated
- Clinical improvement is documented with stable vital signs
- No evidence of ongoing serious infection (negative blood cultures if obtained, resolving inflammatory markers)
Special Considerations During Hospitalization
Monitor for Specific Infections
Given tofacitinib's infection profile, actively evaluate for:
- Herpes zoster (particularly in patients >50 years) 5, 3
- Opportunistic infections including fungal and mycobacterial disease 6
- Bacterial pneumonia and urinary tract infections (most common serious infections)
Age-Related Risk
- Patients ≥69 years have significantly elevated serious infection risk with tofacitinib compared to biologics 7
- By age 76, the risk difference becomes clinically substantial (hazard ratio >1.25) 7
- Consider alternative DMARD strategies in elderly patients with recurrent infections
Common Pitfalls to Avoid
Do not continue tofacitinib "to prevent RA flare" during active infection workup - the mortality and morbidity risk from uncontrolled infection far outweighs the risk of temporary disease activity increase.
Do not restart tofacitinib if fever persists even if cultures are negative - fever itself indicates ongoing inflammatory/infectious process requiring resolution first.
Do not forget thromboprophylaxis - tofacitinib carries a black box warning for thrombosis 2; hospitalized patients should receive appropriate VTE prophylaxis regardless of tofacitinib status.
Alternative Management During Drug Holiday
While tofacitinib is held:
- Short-term glucocorticoids (prednisone 5-10 mg daily) can bridge if RA symptoms worsen 8
- Continue any background methotrexate or other csDMARDs if clinically appropriate and not contraindicated by the acute illness
- Most patients tolerate a 5-7 day interruption without significant RA flare given tofacitinib's rapid offset 4
The benefit-risk calculation strongly favors temporary discontinuation during acute febrile illness - the increased infection risk, particularly serious infections requiring hospitalization, combined with the drug's rapid reversibility makes holding therapy the prudent clinical decision until infection is controlled.